Home/Filings/4/0000950170-25-036694
4//SEC Filing

Rodino-Klapac Louise 4

Accession 0000950170-25-036694

CIK 0000873303other

Filed

Mar 9, 8:00 PM ET

Accepted

Mar 10, 8:00 PM ET

Size

10.3 KB

Accession

0000950170-25-036694

Insider Transaction Report

Form 4
Period: 2025-03-06
Rodino-Klapac Louise
Head of R&D, CSO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-03-06+17,50082,822 total
  • Exercise/Conversion

    Performance Stock Units

    2025-03-0617,5000 total
    Common Stock (17,500 underlying)
  • Tax Payment

    Common Stock

    2025-03-07$103.70/sh7,990$828,56374,318 total
  • Tax Payment

    Common Stock

    2025-03-07$103.70/sh514$53,30282,308 total
Footnotes (3)
  • [F1]Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.
  • [F2]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.
  • [F3]Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.

Documents

1 file

Issuer

Sarepta Therapeutics, Inc.

CIK 0000873303

Entity typeother

Related Parties

1
  • filerCIK 0001836218

Filing Metadata

Form type
4
Filed
Mar 9, 8:00 PM ET
Accepted
Mar 10, 8:00 PM ET
Size
10.3 KB